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Abstract
NPM1 is the most frequently mutated gene
in AML and the role of the NPM1 mutant in
acute myeloid leukemia along with its leuke-
mogenic potential are still under investigation.
NPM1 genetic alterations can contribute to
leukemogenesis through the direct oncogenic
effect of the mutant protein and the concomi-
tant loss of one functional allele. Npm1 loss de-
termines  tumor  development  in  the  mouse
while in human NPM1 maps in a chromosomal
region frequently loss in myelodysplastic syn-
drome (MDS). The NPM1 mutant cytoplasmic
delocalization in leukemic blasts alters mul-
tiple cellular pathways through either loss or
gain  of  function  effects  on  different  protein
partners.
Here we discuss the most relevant studies
on the role of the NPM1 molecule in hemato-
logical malignancies and both in vitro and in
vivo studies that are trying to elucidate the
way  by  which  the  NPM1  mutation  induces
leukemia.
Introduction
NPM1 is a multifunctional phosphoprotein
that encodes for a number of functional do-
mains through which the molecule is able to
bind many partners in distinct cellular com-
partments.1 NPM  displays  nucleolar  localiza-
tion and constantly shuttles between the nu-
cleus and the cytoplasm. The shuttling activity
of  NPM1  along  with  its  capacity  to  interact
with  many  partners  involves  the  protein  in
multiple cellular functions.
These functions include ribosome biogen-
esis and the transport of pre-ribosomal parti-
cles, maintenance of genomic stability through
the control of cellular ploidy and centrosome
duplication and the control of cellular prolifer-
ation. NPM1 is also a survival factor and partic-
ipates  in  DNA-repair  processes.  In  addition,
NPM1 is involved in regulating the activity and
stability of crucial tumor suppressors such as
ARF and p53. The NPM1 polypeptide chain has
a  modular  structure  containing  distinct  se-
quence  motifs  including  a  nuclear-export
signal  (NES)  and  a  nucleolar  localization
signal (NuLS) that resides in the C-terminal
region  of  the  protein.  In  acute  myeloid
leukemia  (AML)  patients  the  NuLS  is  the
target of the C-terminal mutation that deter-
mines its substitution into an extra NES, thus
resulting  in  an  aberrantly  localized  protein
that  resides  in  the  cytoplasm  of  leukemic
blasts.2 The shuttling activity of NPM1 and its
proper sub cellular localization are thought to
be crucial for normal cellular homeostasis and
the identification of the NPM1 mutant coun-
terpart in AML patients has emphasized this
hypothesis. Thus, genetic alteration of NPM1
can contribute to oncogenesis by directly af-
fecting NPM1 functions.
NPM1  has  been  directly  implicated  in
human cancer.1 In fact the NPM1 protein is
overexpressed  in  solid  tumours  of  different
origin like gastric, colon, ovarian and prostate
carcinomas. NPM1 is one of the most frequent
targets of genetic alterations in haematopoi-
etic tumours. It is found translocated with dis-
tinct partner genes in several diseases such as
acute promyelocytic leukemia (APL), anaplastic
large  cell  lymphoma  (ALCL),  acute  myeloid
leukemia  (AML)  and  myelodysplasia.  More-
over, the region of chromosome 5 that NPM1
maps to, is a genetic target of deletions in both
de  novo and  therapy  related  MDS,  a  pre  -
leukemic condition with ineffective production
of myeloid blood cells. More recently NPM1 has
been found mutated and aberrantly localized in
the cytoplasm of myeloid blasts in a high pro-
portion  of  AML  patients  with  normal  kary-
otype.2 Although the NPM1 gene was strongly
implicated in cancer pathogenesis, how the cy-
toplasmic  localized  NPM1  mutant  protein
(NPMc+) promotes leukemia is still under in-
vestigation.
NPM1 gene alterations 
contributing to leukemogenesis
The  alteration  of  NPM1  in  human  cancer
can lead to tumor development as a result of
two  major  mechanisms  involving  both  the
presence of a mutated product and the reduc-
tion of the wild type NPM1 dosage and level of
expression.  Indeed,  NPM1  gene  alterations
lead to the generation of mutated products as-
sociated with hematopoietic malignancies (in
the case of AML the NPMc+ mutant), and to
the concomitant loss of one functional allele of
the gene leading to NPM1 heterozygosity.
The reduction of the NPM dosage to het-
erozygosity has been shown to lead to altered
NPM1 functions and tumour susceptibility3 in-
dicating that normal levels of expression are
required for the cell to prevent tumor develop-
ment. Moreover mutated products retain the
ability  to  heterodimerize  with  the  residual
wild-type  protein,  and  they  potentially  inter-
fere with its functions. In particular the domi-
nant-negative effect of the mutated NPM de-
termines the delocalization of the remaining
wild-type  NPM  protein  and  exacerbates  the
NPM functional loss. On the other end there is
the capability for the NPMc+ mutant itself to
function  as  activated  oncogene.  Since  the
NPM1 mutation always results in aberrant cy-
toplasmic  dislocation  of  the  mutant  protein,
this event appears critical for leukemogenesis.
The increased NPM1 export into the cytoplasm
can affect multiple cellular pathways and drive
leukemia  by  either  a  loss-of-function4,5 or  a
gain-of-function.6In fact, the NPMc+ nucleolar
interactors can be delocalized by the mutant
into leukemic cells cytoplasm and their activity
can be significantly impaired. On the other end
the NPMc+ mutant may acquire the capability
to interact with new protein partners in the cy-
toplasm.  All  these  activities  can  lead  to
leukemia and there are a number of in vitro
and  in  vivo data  supporting  this  hypothesis
that will be analyzed in the next paragraphs.
The role of Npm functional loss in
tumor development
Data on the role of Npm functional loss in
tumor  development  arise  from  mouse  work
that has been done in the Pandolfi’s lab in the
last  five  years.  Npm  complete  knockout  re-
sulted in embryonic lethality due to develop-
mental abnormalities of the brain and of the
hematopoietic system.3 In this setting Npm in-
activation was able to determine cancer sus-
ceptibility in vitro. The other main observation
of this study implicated Npm in the pathogen-
esis of human MDS. Npm heterozygous mice
showed  some  of  the  features  found  in  the
human  syndrome.  Peripheral  blood  showed
significantly increased MCV and RDW values
while the bone marrow presented a high pro-
portion of dysplastic erythroid precursors and
megakaryocyte  dyspoiesis.  This  MDS  status
evolved  into  overt  leukemia  as  in  humans,
demonstrating  that  Npm  act  as  tumor  sup-
pressor gene in vivo.7 In fact, Npm1 heterozy-
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gous  mice  displayed  higher  susceptibility  to
develop  tumor  than  their  wild  type  counter-
parts (29% vs 6,3%). Pathological analysis re-
vealed that 75% of the diseased mice were af-
fected  by  hematological  malignancies,  in-
cluding myeloid leukemia, while no abnormal-
ities were detected in the hematopoietic or-
gans of wild type animals analyzed. Npm loss
of  function  at  the  centrosome  has  been  in-
volved in tumor development in these mice as
bone marrow cytospins from blasts of affected
mice clearly showed an increased number of
cells displaying multiple centrosomes.
Is NPMc+ an oncogene in vitro?
Until very recently there was no published
evidence that NPMc+ would transform primary
cells in vitro. At first, the NPMc+ oncogenic ca-
pacity in vitrohas been debated as a study sug-
gested a tumor suppressive role for the NPMc+
mutant because its overexpression in ARF null
cells end up inhibiting cell proliferation.8
In order to establish whether NPMc+ is an
oncogene in vitro, the effect of NPMc+ overex-
pression  in  primary  MEFs  has  been  studied
performing classical oncogenic transformation
assays in soft agar.9 The study demonstrated
that NPMc+ is able to transform when it is
combined with E1A. E1A is an adenoviral onco-
gene that induces a E2F1-dependent cell cycle
progression. At the same time it induces apop-
tosis through Arf and p53. NPMc+ blocks Arf,
allowing E1A to evade the p53 induced apop-
tosis in transformed cells while the addition of
E1A completely abolishes the NPMc+ induced
senescent  phenotype  and  allows  transforma-
tion. This represented the first demonstration
that NPMc+ is an oncogene in vitro and sug-
gested  the  need  for  a  cooperative  event  in
leukemogeneis.
Data arising from other studies described a
model in which mutations of NPM1 seem to si-
multaneously  dampen  a  tumor-suppressor
pathway4 (p53–ARF)  and  enhance  an  onco-
genic one (MYC).5 In fact, NPMc+ was demon-
strated to be able to reduce the ability of ARF to
initiate a p53 response and to induce cell cycle
arrest. Bonetti et al. show that, in the absence
of NPM or in the presence of NPMc+, FBW7γ
loses its nucleolar localization and is rapidly
degraded by the proteasome. FBW7γis a nucle-
olar ubiquitin ligase previously implicated in
the  ubiquitination/degradation  of  MYC.
NPMc+ maintains the property of interacting
with FBW7γ but delocalizes it to the cytoplasm,
where it is degraded, thus leading to accumu-
lation of MYC and increased MYC signaling.
The NPM1 mutant may also exert its trans-
forming properties through gain-of function in
cytoplasm.6 Interestingly,  the  NPM1  mutant
binds caspase 6 and 8 in the cytoplasm and
specifically inhibits the activities of these cell-
death caspases through direct interaction with
their cleaved active forms. Moreover NPMc+ is
able  to  suppress  caspase  6  and  8-mediated
myeloid differentiation.
Is NPMc+ an oncogene in vivo?
Until very recently there was no published
data on NPMc+ oncogenic activity in vivo. How-
ever, cytoplasmic mutated NPM has been re-
tained for eight years in a xenotransplant model
of NPMc+ acute myeloid leukemia in immunod-
eficient mice by subcutaneous injection of AML
blasts from a patient.10This study demonstrated
that cytoplasmic mutated NPM1 is stable in AML
and suggested that the NPM1 mutation repre-
sent a founder genetic lesion in AML.
In an attempt to understand the in vivo role
of NPMc+ in AML, it has been recently devel-
oped a model showing an impact of the muta-
tion on myelopoiesis with no progression to-
ward  overt  leukemia.11 NPMc+  was  overex-
pressed under the control of the MRP8 promoter
which  lead  the  expression  of  NPMc+  in  the
common myeloid progenitors as well as mature
granulocytes and monocytes. These mice came
down  with  myeloproliferative  disorders  with
splenomegaly  and  increased  number  of  Gr-
1Mac-1  mature  myeloid  cells  in  the  bone
marrow and spleen. However, the latency was
long and the phenotype was not fully penetrant
among the different line analyzed and, more im-
portantly, the NPM1 mutant alone was not able
to initiate AML. Consequently, to exert its onco-
genic effect, NPM1 may need to act under dif-
ferent conditions, such as targeting a specific
stem cell/myeloid precursor and/or achieving a
mutant to wild-type expression ratio that is ap-
propriate for cytoplasmic delocalization of both
nucleophosmin  forms  and/or  being  accompa-
nied by a secondary cooperating event. How-
ever, the fact that NPMc+ is a bona fide onco-
gene in vivo comes from another interesting
finding  that  NPMc+  also  drives  epithelial
cancer given the fact that MRP8 is a leaky pro-
moter in skin. Considering MRP8 is leaky in the
keratinocytes,  this  presumably  demonstrates
that NPMc+ is an oncogene in vivo.
Data on zebrafish completely confirm what
shown in the MRP8-NPMc+ transgenic mouse
model.12 In  zebrafish,  ubiquitous  mutant
NPMc+ not only caused expansion of primitive
myeloid cells, but also resulted in increased
numbers of definitive erythro-myeloid progen-
itors  (gata1+/lmo2bright)  and  hematopoietic
stem cells (c-myb+/cd41+) in the aorta ventral
wall.  In  the  zebrafish  embryo,  follow-up  for
AML development was not possible due to the
transient nature of mutant NPM1 expression.
More recently a conditional knock-in allele
of  the  NPM1  mutation  A  demonstrated  that
NPMc+  causes  acute  myeloid  leukemia  in
mice.13 NPMc+ heterozygous activation in the
hematopoietic system was associated with ex-
pansion  of  mature  bone  marrow  mature
myeloid cells as previously described. Knock-in
mutant display increased incidence of acute
myeloid and lymphoid leukemias arising with
a long latency suggesting the requirement for
additional mutations. Insertional mutagenesis
screens  in  vivo  accelerated  leukemia  onset
confirming the need for cooperative events in
NPMc+ leukemogenesis.
Conclusions
The  potential  role  of  the  NPM  mutant  as
oncogene as well as the aberrant mechanism
that leads to leukaemogenesis in NPMc+ AML
is still under investigation. Here we have pre-
sented  the  most  relevant  studies  describing
how  NPM1  alterations  could  contribute  to
leukemia. NPM1 expression and gene integrity
are frequently altered in human hematological
malignancies.  Thus,  the  pathogenesis  of
NPMc+ AML has been proposed to depend on
both NPM functional loss and the NPMc+ mu-
tant oncogenic activity.
Genetic  and  molecular  evidence  has  shed
light  on  the  mechanisms  of  NPM-mediated
tumor suppression, demonstrating that Npm is
a haploinsufficient suppressor of both myeloid
and  lymphoid  malignancies  in  the  mouse.
NPMc+ is able to exert oncogenic potential by
either loss or gain of function effects that im-
pact on multiple cellular pathways. It has been
demonstrated that NPMc+ act as a bona fide
proto-oncogene in vitro and in vivo and sug-
gested that additional cooperative genetic hits
are  required  for  leukemogenesis.  Knock-in
mouse models mimicking human NPM1-mu-
tated AML are still under development and will
be  essential  tools  in  the  discovery  of  novel
NPMc+ leukemogenic activities.
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